Latest Ganirelix Stories
With new information available, authors of a Cochrane Systematic Review have revised their conclusions about the relative effectiveness of two different treatments used to help women become pregnant.
Giving women gonadotrophin-releasing hormone (GnRH) antagonists leads to similar live-birth rates compared with GnRH agonists, according to a new study.
Previous work in birds and sheep shows a wealth of clinical possibilities.
ATLANTA, Oct. 20 /PRNewswire/ -- Ferring Pharmaceuticals presented an interim study analysis indicating that MENOPURÂ® (menotropins for injection, USP) is effective in in vitro fertilization (IVF) cycles using a gonadotropin-releasing hormone (GnRH) antagonist.
PARSIPPANY, N.J., Aug. 4 /PRNewswire/ -- Ferring Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved the trade name FIRMAGON(R) (degarelix for injection) for its prostate cancer treatment previously marketed under the generic name degarelix.
Neurocrine Biosciences, a biopharmaceutical company, has announced positive safety and efficacy results from its third Phase II clinical trial using its proprietary, orally-active nonpeptide gonadotropin-releasing hormone receptor antagonist, elagolix, in patients with endometriosis.
- A poem in which the author retracts something said in an earlier poem.